Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence
Helgi Thor Hjartarson,1 Kristofer Nathorst-Böös,1 Thomas Sejersen1,2 1Department of Neuropediatrics, Astrid Lindgren Children´s Hospital, Karolinska University Hospital, Stockholm, Sweden; 2Department of Women’s and Children’s Health, Karolinska Institute, Stockholm, SwedenCorrespondence: Thomas Sej...
Main Authors: | Hjartarson HT, Nathorst-Böös K, Sejersen T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-06-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/disease-modifying-therapies-for-the-management-of-children-with-spinal-peer-reviewed-fulltext-article-DDDT |
Similar Items
-
Oral risdiplam for specific therapy in adult patients with 5q spinal muscular atrophy in the Moscow region
by: Ekaterina S. Novikova
Published: (2023-09-01) -
Rehabilitation in spinal muscular atrophy
by: Joanna Iłżecka
Published: (2021-05-01) -
Sensory changes in pediatric patients with spinal muscular atrophy: an electrophysiologic study
by: Hussien E Sultan, et al.
Published: (2016-01-01) -
Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen
by: Pol Andrés-Benito, et al.
Published: (2024-03-01) -
Spinal Muscular Atrophy With Myoclonic Epilepsy
by: Buket ÖZKARA, et al.
Published: (2017-04-01)